Literature DB >> 3752145

Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients.

H M Lederman, C M Roifman, S Lavi, E W Gelfand.   

Abstract

Severe adverse reactions to intravenous immune serum globulin occurred repeatedly in four of 10 hypogammaglobulinemic patients. Treatment-limiting symptoms included fever, chills, headache, hypertension, and chest pain. Pretreatment of patients with hydrocortisone immediately prior to infusion prevented subsequent adverse reactions and permitted these patients to receive immune serum globulin intravenously.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752145     DOI: 10.1016/0002-9343(86)90296-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.

Authors:  R John Looney
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-01-15       Impact factor: 8.262

4.  Dosing and therapy utilization: a discussion of updates on PI treatment guidelines.

Authors:  Mark Ballow
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

Review 5.  Hypogammaglobulinemia: therapeutic rationale.

Authors:  A A Long; J A Denburg; P B Dent
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

6.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

7.  Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

Authors:  Hans D Ochs; Sudhir Gupta; Peter Kiessling; Uwe Nicolay; Melvin Berger
Journal:  J Clin Immunol       Date:  2006-05       Impact factor: 8.542

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.